Ikena Oncology Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(40,110) | $(48,677) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 401 | 715 |
| Net accretion of discounts on marketable securities | (1,183) | (1,709) |
| Stock-based compensation | 4,297 | 5,877 |
| Non-cash operating lease expense | 1,526 | 1,152 |
| Loss on disposal of property and equipment | 99 | 5 |
| Impairment of assets held for sale | 742 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (327) | 1,271 |
| Deposits and other assets | 2,390 | (429) |
| Accounts payable | (526) | (987) |
| Accrued expenses and other current liabilities | (4,804) | (5,308) |
| Operating lease liabilities | (2,344) | (1,333) |
| Deferred revenue | — | (8,501) |
| Other long-term liabilities | 95 | — |
| Net cash used in operating activities | (39,744) | (57,924) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (152) |
| Proceeds from sale of property and equipment | 435 | 4 |
| Purchases of marketable securities | (81,036) | (65,217) |
| Proceeds from maturities of marketable securities | 45,235 | 109,133 |
| Net cash provided by (used in) investing activities | (35,366) | 43,768 |
| Cash flows from financing activities: | ||
| Cash and cash equivalents acquired in connection with the acquisition of Pionyr, net of issuance costs paid | — | 39,970 |
| Cash consideration paid in connection with the acquisition of Pionyr | — | (944) |
| Proceeds from issuance of common stock for underwritten registered offering, net of offering costs | — | 37,421 |
| Repurchase of common stock | — | (663) |
| Proceeds from exercise of stock options | — | 136 |
| Net cash provided by financing activities | — | 75,920 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (75,110) | 61,764 |
| Cash, cash equivalents and restricted cash, beginning of period | 121,172 | 60,791 |
| Cash, cash equivalents and restricted cash, end of period | $46,062 | $122,555 |
| Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $45,190 | $121,277 |
| Restricted cash included in other assets | 872 | 1,278 |
| Cash, cash equivalents and restricted cash, end of period | $46,062 | $122,555 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.